Banyai-Falger S, Susani M, Maier U
Department of Internal Medicine III, University of Vienna, Medical School, Austria.
Eur Urol. 1995;28(1):77-80. doi: 10.1159/000475025.
Acquired renal cystic disease (ARCD) has a prevalence of up to 90% in patients with endstage renal failure and an uncommonly high potential of developing into renal cell carcinoma. After renal transplantation, regression of an established ARCD is possible, suggesting a protective effect of transplantation against tumors in the native kidneys. Two case reports describing hypernephromas in kidneys with ARCD 3 years after successful renal transplantation are presented. One patient died 6 weeks after nephrectomy due to metastatic disease, although there were no metastases at the time of operation. The other patient lives with no evidence of disease since 10 months. This report confirms the need of annual sonography of the native kidneys also in renal transplant patients with consecutive computed tomography scanning of suspicious lesions.
获得性肾囊肿疾病(ARCD)在终末期肾衰竭患者中的患病率高达90%,且发展为肾细胞癌的可能性异常高。肾移植后,已形成的ARCD有可能消退,提示移植对天然肾脏肿瘤具有保护作用。本文报告2例成功肾移植3年后ARCD肾脏发生肾细胞癌的病例。1例患者肾切除术后6周因转移性疾病死亡,尽管手术时并无转移灶。另1例患者自术后10个月起存活,无疾病证据。本报告证实,对于肾移植患者,也需要每年对天然肾脏进行超声检查,并对可疑病变进行连续计算机断层扫描。